Shelley Stanko, MD
Family Medicine · London, KYNPI 1043232101
Payments from drug & device makers
Across 398 payments — averaging $14.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$710
- Pfizer$695
- Amgen$587
- Novo Nordisk$520
- Lilly USA, LLC$473
- Astellas Pharma US Inc$402
- plus $2K from 29 others
What the payments were for
- Food & beverage$5,73499%
- Education$751%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 48 | $710 |
| Pfizer | 43 | $695 |
| Amgen(2 entities) | 36 | $587 |
| Novo Nordisk | 32 | $520 |
| Lilly USA, LLC | 32 | $473 |
| Astellas Pharma US Inc | 24 | $402 |
| Boehringer Ingelheim | 34 | $383 |
| Takeda Pharmaceuticals U.S.A., Inc. | 20 | $252 |
| Novartis | 13 | $208 |
| Merck | 24 | $198 |
| AstraZeneca(2 entities) | 14 | $186 |
| Bayer | 8 | $162 |
| Amarin Pharma, Inc. | 12 | $158 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $112 |
| Sanofi-aventis U.S. LLC | 8 | $112 |
| Biohaven Pharmaceuticals, Inc. | 7 | $99 |
| Johnson & Johnson | 5 | $75 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $65 |
| Teva Pharmaceuticals USA, Inc. | 4 | $54 |
| Kowa Pharmaceuticals America, Inc. | 3 | $48 |
| GSK | 3 | $45 |
| Genentech USA, Inc. | 2 | $37 |
| Lundbeck LLC | 2 | $36 |
| Antares Pharma, Inc. | 1 | $28 |
| E.r. Squibb & Sons, L.L.C. | 2 | $27 |
| Abbott | 1 | $18 |
| Ultragenyx Pharmaceutical Inc. | 1 | $18 |
| Sumitomo Pharma America, Inc. | 1 | $16 |
| UCB, Inc. | 1 | $14 |
| Melinta Therapeutics, LLC | 1 | $14 |
| Neurocrine Biosciences, Inc. | 1 | $14 |
| Esperion Therapeutics, Inc. | 1 | $12 |
| Arbor Pharmaceuticals, Inc. | 1 | $12 |
| Idorsia Pharmaceuticals US Inc | 1 | $12 |
| Inogen, Inc. | 1 | $11 |
How this compares
$5,809 in reported general payments places this provider in the 85th percentile of 1,559 family medicine providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 374 | $162,428 |
| IngrezzaValbenazine Tosylate | 11 | $91,812 |
| MounjaroTirzepatide | 49 | $65,095 |
| OzempicSemaglutide | 60 | $63,863 |
| JanuviaSitagliptin Phosphate | 38 | $60,271 |
| JardianceEmpagliflozin | 79 | $43,144 |
| FarxigaDapagliflozin Propanediol | 41 | $27,791 |
| MultaqDronedarone Hcl | 44 | $22,997 |
| RybelsusSemaglutide | 18 | $22,847 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 34 | $17,372 |
| TrulicityDulaglutide | 12 | $16,765 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $15,472 |
| Xigduo XrDapaglifloz Propaned/Metformin | 19 | $15,469 |
| LinzessLinaclotide | 14 | $12,061 |
| Repatha SureclickEvolocumab | 16 | $11,979 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $695 | $162,428374 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $14 | $91,81211 claims |
| Novo NordiskOzempic, Rybelsus | $520 | $86,71078 claims |
| Lilly USA, LLCMounjaro, Trulicity | $473 | $81,85961 claims |
| MerckJanuvia, Janumet Xr | $198 | $77,64372 claims |
| Boehringer IngelheimJardiance, Synjardy, Spiriva Respimat | $383 | $61,423105 claims |
| AstraZenecaFarxiga | $186 | $27,79141 claims |
| Sanofi-aventis U.S. LLCMultaq | $112 | $22,99744 claims |
| AbbVieLinzess, Synthroid | $710 | $18,115109 claims |
| GSKTrelegy Ellipta | $45 | $10,76411 claims |
| Astellas Pharma US IncMyrbetriq | $402 | $10,24078 claims |
| Teva Pharmaceuticals USA, Inc.Acyclovir | $54 | $2,84021 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,559 family medicine providers in Kentucky.
Other family medicine in London
- Jackie MaxeyLondon$12K
- Brian SmithVersailles$7.7M
- Barbara Fleming-PhillipsLexington$1.4M
- Christopher RhyneLouisville$1M
- Kruti PatelBurlington$463K
- Michael LovelaceLouisville$244K
- John RichardLexington$226K
- Diego MastronardiBowling Green$196K
- James TurnboPaducah$124K
- Eleida Tur OlivaLexington$113K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.